Elda Perlino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elda Perlino has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Eugenio Maiorano
Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy
11 shared publications Ersilia Marra
10 shared publications- Giuseppe Loverro
School of Medicine, University of Bari
5 shared publications Luigi Selvaggi
5 shared publicationsE Marra
Centro di Studio sui Mitocondri e Metabolismo Energetico, C.N.R., Bari, I-70126 Bari, Italy
4 shared publicationsMargherita Greco
4 shared publications
Latest Publications
- Open Access
- 4 February 2021
- Published by MDPI AG in Electronics
- Vol. 10 (4) , 375
Explaining Ovarian Cancer Gene Expression Profiles with Fuzzy Rules and Genetic Algorithms
The analysis of gene expression data is a complex task, and many tools and pipelines are available to handle big sequencing datasets for case-control (bivariate) studies. In some cases, such as pilot or exploratory studies, the researcher needs to compare more than two groups of samples consisting of a few replicates. Both standard statistical bioinformatic pipelines and innovative deep learning models are unsuitable for extracting interpretable patterns and information from such datasets. In this work, we apply a combination of fuzzy rule systems and genetic algorithms to analyze a dataset composed of 21 samples and 6 classes, useful for approaching the study of expression profiles in ovarian cancer, compared to other ovarian diseases. The proposed method is capable of performing a feature selection among genes that is guided by the genetic algorithm, and of building a set of if-then rules that explain how classes can be distinguished by observing changes in the expression of selected genes. After testing several parameters, the final model consists of 10 genes involved in the molecular pathways of cancer and 10 rules that correctly classify all samples.
- 4 February 2021
- Published by MDPI AG in Electronics
- Vol. 10 (4) , 375
Open AccessExplaining Ovarian Cancer Gene Expression Profiles with Fuzzy Rules and Genetic Algorithms
The analysis of gene expression data is a complex task, and many tools and pipelines are available to handle big sequencing datasets for case-control (bivariate) studies. In some cases, such as pilot or exploratory studies, the researcher needs to compare more than two groups of samples consisting of a few replicates. Both standard statistical bioinformatic pipelines and innovative deep learning models are unsuitable for extracting interpretable patterns and information from such datasets. In this work, we apply a combination of fuzzy rule systems and genetic algorithms to analyze a dataset composed of 21 samples and 6 classes, useful for approaching the study of expression profiles in ovarian cancer, compared to other ovarian diseases. The proposed method is capable of performing a feature selection among genes that is guided by the genetic algorithm, and of building a set of if-then rules that explain how classes can be distinguished by observing changes in the expression of selected genes. After testing several parameters, the final model consists of 10 genes involved in the molecular pathways of cancer and 10 rules that correctly classify all samples.
- Open Access
- 1 January 2018
- Published by Open Access Text Pvt, Ltd. in Biomedical Research and Reviews
- Vol. 2 (1)
NGS approach for new ovarian cancer biomarker discovery Ovarian cancer biomarker discovery
- 1 January 2018
- Published by Open Access Text Pvt, Ltd. in Biomedical Research and Reviews
- Vol. 2 (1)
Open AccessNGS approach for new ovarian cancer biomarker discovery Ovarian cancer biomarker discovery
- Open Access
- 2 May 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-10
Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?
Clusterin (CLU) is a ubiquitous multifunctional factor involved in neoplastic transformation. The CLU transcript variants and protein forms play a crucial role in balancing cells proliferation and death. We investigated the regulation of CLU transcript variants expression in an in vivo model system consisting of both neoplastic tissues and fine needle aspiration biopsy (FNAB) samples isolated from patients undergoing thyroidectomy. The immunohistochemical analyses showed an overall CLU up-regulation in papillary carcinoma. A specific CLU2 transcript variant increase was registered using qPCR in papillary carcinomas while CLU1 decreased. In addition, the analysis of CLU transcripts expression level showed an increase of the CLU2 transcript in the TIR 3 patients with histologically confirmed thyroid cancer. Our results suggest the existence of a specific alteration of CLU2:CLU1 ratio towards CLU2, thus providing the first circumstantial evidence for the potential use of CLU transcript variants as effective biomarkers for a more accurate assessment of the so called “indeterminate” thyroid nodules.
- 2 May 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-10
Open AccessClusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?
Clusterin (CLU) is a ubiquitous multifunctional factor involved in neoplastic transformation. The CLU transcript variants and protein forms play a crucial role in balancing cells proliferation and death. We investigated the regulation of CLU transcript variants expression in an in vivo model system consisting of both neoplastic tissues and fine needle aspiration biopsy (FNAB) samples isolated from patients undergoing thyroidectomy. The immunohistochemical analyses showed an overall CLU up-regulation in papillary carcinoma. A specific CLU2 transcript variant increase was registered using qPCR in papillary carcinomas while CLU1 decreased. In addition, the analysis of CLU transcripts expression level showed an increase of the CLU2 transcript in the TIR 3 patients with histologically confirmed thyroid cancer. Our results suggest the existence of a specific alteration of CLU2:CLU1 ratio towards CLU2, thus providing the first circumstantial evidence for the potential use of CLU transcript variants as effective biomarkers for a more accurate assessment of the so called “indeterminate” thyroid nodules.
- 11 April 2013
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 42 (6) , 1929-1944
Regulation of the expression of CLU isoforms in endometrial proliferative diseases
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 11 April 2013
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 42 (6) , 1929-1944
Regulation of the expression of CLU isoforms in endometrial proliferative diseases
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 1 May 2012
- Published by Elsevier in Cancer Letters
- Vol. 318 (2) , 135-144
Regulation of TGF-β1 expression by Androgen Deprivation Therapy of prostate cancer
- 1 May 2012
- Published by Elsevier in Cancer Letters
- Vol. 318 (2) , 135-144
Regulation of TGF-β1 expression by Androgen Deprivation Therapy of prostate cancer
- Open Access
- 22 July 2011
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 39 (5) , 1233-1242
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer
BCL-2 is an integral protein of the external mitochondrial membrane that inhibits cell apoptotic death. We investigated the effect of androgen deprivation therapy (ADT) on BCL-2 expression in prostate cancer tissues. We studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant ADT, by Northern and Western blot analysis, and immunohistochemistry. Moreover, gene transcriptional activity was also measured by nuclear run-on experiments. We demonstrated an increase of BCL-2 mRNA expression in patients who underwent neoadjuvant ADT for 1 month in comparison to patients who had not received any therapy. Moreover, we demonstrated that there were no significant modifications of BCL-2 mRNA levels in patients who underwent neoadjuvant ADT for 3 and 6 months. Furthermore, BCL-2 protein levels in patients who underwent neoadjuvant ADT for 1 month were upregulated in comparison to patients who had not received any therapy. Immunohistochemical analysis showed a strong positivity of prostate cells depending on ADT administration for 1 month. Finally, transcriptional activity was not modified in patients who underwent neoadjuvant ADT, suggesting the absence of hormonal regulation on BCL-2 gene expression at the transcriptional level. Our data show that short-term administration of ADT interferes with BCL-2 expression, suggesting that androgen-mediated mechanisms may act through BCL-2-mediated apoptotic pathways. Moreover, since short-term ADT administration does not interfere with BCL-2 expression at the transcriptional level, the androgen-mediated mechanisms involving BCL-2 pathways, probably act at the post-transcriptional level.
- 22 July 2011
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 39 (5) , 1233-1242
Open AccessAndrogen deprivation therapy affects BCL-2 expression in human prostate cancer
BCL-2 is an integral protein of the external mitochondrial membrane that inhibits cell apoptotic death. We investigated the effect of androgen deprivation therapy (ADT) on BCL-2 expression in prostate cancer tissues. We studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant ADT, by Northern and Western blot analysis, and immunohistochemistry. Moreover, gene transcriptional activity was also measured by nuclear run-on experiments. We demonstrated an increase of BCL-2 mRNA expression in patients who underwent neoadjuvant ADT for 1 month in comparison to patients who had not received any therapy. Moreover, we demonstrated that there were no significant modifications of BCL-2 mRNA levels in patients who underwent neoadjuvant ADT for 3 and 6 months. Furthermore, BCL-2 protein levels in patients who underwent neoadjuvant ADT for 1 month were upregulated in comparison to patients who had not received any therapy. Immunohistochemical analysis showed a strong positivity of prostate cells depending on ADT administration for 1 month. Finally, transcriptional activity was not modified in patients who underwent neoadjuvant ADT, suggesting the absence of hormonal regulation on BCL-2 gene expression at the transcriptional level. Our data show that short-term administration of ADT interferes with BCL-2 expression, suggesting that androgen-mediated mechanisms may act through BCL-2-mediated apoptotic pathways. Moreover, since short-term ADT administration does not interfere with BCL-2 expression at the transcriptional level, the androgen-mediated mechanisms involving BCL-2 pathways, probably act at the post-transcriptional level.
- 1 March 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (7) , 729-735
The IGF-I Axis in Thyroid Carcinoma
Insulin like-growth factor I (IGF-I) has been involved in the pathogenesis of a variety of human neoplasia due to the mitogenic and anti-apoptotic properties of its cognate receptor. In human thyroid carcinomas, we have previously documented an increased immunoreactivity of both IGF-I and the IGF-I receptor (IGF-I R) associated with up regulation of IGF-I mRNA . Immunoreactivity of IGF-I and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients gender and age or with the stage of the tumors and the occurrence of limph node metastases. Most experimental studies indicate that the effects of IGF-I on target cells are regulated in a complex fashion and depend on the simultaneous occurrence of IGF-IR and the binding proteins.
- 1 March 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (7) , 729-735
The IGF-I Axis in Thyroid Carcinoma
Insulin like-growth factor I (IGF-I) has been involved in the pathogenesis of a variety of human neoplasia due to the mitogenic and anti-apoptotic properties of its cognate receptor. In human thyroid carcinomas, we have previously documented an increased immunoreactivity of both IGF-I and the IGF-I receptor (IGF-I R) associated with up regulation of IGF-I mRNA . Immunoreactivity of IGF-I and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients gender and age or with the stage of the tumors and the occurrence of limph node metastases. Most experimental studies indicate that the effects of IGF-I on target cells are regulated in a complex fashion and depend on the simultaneous occurrence of IGF-IR and the binding proteins.
- 1 February 2005
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 26 (2) , 457-465
Transcriptional regulation of β1 integrin expression in the physio/pathological states of human endometrial tissues
β1C integrin is a spliced variant of the human β1 integrin family that inhibits cell proliferation, at variance with β1A that stimulates it. During the transition from normal to neoplastic endometrium, both variants are down-regulated at the mRNA level, but only β1C at the protein level, suggesting a key role of the regulation of β1C integrin expression in the pathogenesis of endometrial cancer. In this study we show for the first time that, besides β1A and β1C, the β1B spliced variant is expressed in human endometrium, and is up-regulated in hyperplastic and neoplastic endometria in comparison with normal proliferative endometria. To investigate the mechanisms of regulation of β1 integrin expression during endometrial cancer progression we compared the transcriptional activity of the β1 integrin gene in normal and diseased endometria by nuclear run-on analysis and we found it significantly reduced in endometrial adenocarcinoma. On the contrary, hyperplastic endometria showed a 2-fold increase in the β1 transcription rate that directly correlated with the increase in β1B, β1C and β1A steady-state mRNA levels. Finally, we compared the activity of the distal and proximal promoters of the β1 gene integrin gene in normal and diseased endometria and we found the activity of the proximal promoter decreased in neoplastic endometria and increased in hyperplastic tissues, whereas the activity of the distal promoter did not change in different endometrial physio/pathological conditions. These findings suggest a complex pattern for regulation of the expression of β1 integrin variants during endometrial malignant transformation.
- 1 February 2005
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 26 (2) , 457-465
Transcriptional regulation of β1 integrin expression in the physio/pathological states of human endometrial tissues
β1C integrin is a spliced variant of the human β1 integrin family that inhibits cell proliferation, at variance with β1A that stimulates it. During the transition from normal to neoplastic endometrium, both variants are down-regulated at the mRNA level, but only β1C at the protein level, suggesting a key role of the regulation of β1C integrin expression in the pathogenesis of endometrial cancer. In this study we show for the first time that, besides β1A and β1C, the β1B spliced variant is expressed in human endometrium, and is up-regulated in hyperplastic and neoplastic endometria in comparison with normal proliferative endometria. To investigate the mechanisms of regulation of β1 integrin expression during endometrial cancer progression we compared the transcriptional activity of the β1 integrin gene in normal and diseased endometria by nuclear run-on analysis and we found it significantly reduced in endometrial adenocarcinoma. On the contrary, hyperplastic endometria showed a 2-fold increase in the β1 transcription rate that directly correlated with the increase in β1B, β1C and β1A steady-state mRNA levels. Finally, we compared the activity of the distal and proximal promoters of the β1 gene integrin gene in normal and diseased endometria and we found the activity of the proximal promoter decreased in neoplastic endometria and increased in hyperplastic tissues, whereas the activity of the distal promoter did not change in different endometrial physio/pathological conditions. These findings suggest a complex pattern for regulation of the expression of β1 integrin variants during endometrial malignant transformation.
- RetractedOpen Access
- 1 January 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (3) , 1692-1702
Regulation of β1C and β1A Integrin Expression in Prostate Carcinoma Cells
- 1 January 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (3) , 1692-1702
RetractedOpen AccessRegulation of β1C and β1A Integrin Expression in Prostate Carcinoma Cells
- 1 December 2003
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 23 (6) , 1601-1606
Transcriptional regulation of the β1C integrin splice variant in human prostate adenocarcinoma
Members of the integrin family of cell adhesion receptors influence several important aspects of cancer cell behaviour, including motility and invasiveness, cell growth and cell survival. β1C integrin, an alternatively spliced variant of the human β1 integrin, has been shown to inhibit cell proliferation. We have previously demonstrated that β1C integrin mRNA and protein are present in normal prostate and are down-regulated in prostate adenocarcinoma. To explore some of the molecular mechanisms regulating β1C integrin gene expression, we have analysed the transcriptional activity of the β1 integrin gene in neoplastic and normal human prostate tissue. Run-on analysis demonstrates that the transcription rate of the β1 integrin gene is significantly reduced in prostate cancer specimens compared to normal prostate, thus accounting for the reduction in mRNA levels of the β1 integrin variants. Moreover, the decrease in transcriptional activity of the β1 integrin gene directly correlates to the reduction of β1C integrin steady-state mRNA levels (r=0.78).
- 1 December 2003
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 23 (6) , 1601-1606
Transcriptional regulation of the β1C integrin splice variant in human prostate adenocarcinoma
Members of the integrin family of cell adhesion receptors influence several important aspects of cancer cell behaviour, including motility and invasiveness, cell growth and cell survival. β1C integrin, an alternatively spliced variant of the human β1 integrin, has been shown to inhibit cell proliferation. We have previously demonstrated that β1C integrin mRNA and protein are present in normal prostate and are down-regulated in prostate adenocarcinoma. To explore some of the molecular mechanisms regulating β1C integrin gene expression, we have analysed the transcriptional activity of the β1 integrin gene in neoplastic and normal human prostate tissue. Run-on analysis demonstrates that the transcription rate of the β1 integrin gene is significantly reduced in prostate cancer specimens compared to normal prostate, thus accounting for the reduction in mRNA levels of the β1 integrin variants. Moreover, the decrease in transcriptional activity of the β1 integrin gene directly correlates to the reduction of β1C integrin steady-state mRNA levels (r=0.78).